Drugmaker Impax Laboratories Inc. accepted an illegal payment from Endo Pharmaceuticals Inc. in exchange for delaying the market entry of Impax’s generic form of Endo’s opioid pain medication Opana ER, the U.S. Federal Trade Commission said Friday…
Read this piece in its entirety at Law360.
